The New Math of Drug-Device Convergence

In combination products that span the device and pharmaceutical industry, one plus one doesn't necessarily equal three. Speaking at "Convergence: the Drug/Device Summit," Paul LaViolette, chief operating office of Boston Scientific, recounts the intricacies of getting Taxus, the largest combination product in history, to market. For all the success BSC has had, both with Taxus and generally speaking--a huge infrastructure, billions of dollars in revenues, and 18 PMA approvals under its belt-the first lesson it learned from its drug-eluting stent program was, "As hard as you think it may be, it's harder than that."

In Pittsburgh in mid-March, some 140 drug, device, biomaterial, and venture capital firms gathered at "Convergence: the Drug/Device Summit," to suss out the next major product opportunities to come from combining drugs and devices. The conference was organized by Bio and AdvaMed, advocacy groups for the biotechnology and device industries respectively, as well as the incubator Pittsburgh Life Sciences Greenhouse and Windhover Information Inc. The device and drug industries are pinning great hopes on convergence, since the highest profile example—the drug eluting stent—is already an almost $5 billion market that's forecast to grow to $10 billion by 2009.

But drug-eluting stents, notwithstanding their success, only skim the surface of possible drug/device convergence: already, BMP products such as Medtronic...

Welcome to In Vivo

Create an account to read this article

More from Leadership

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Execs On The Move: June 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.